Influence of secondary sources in the Brief Negative Symptom Scale.
García-Portilla, Maria Paz
MetadataShow full item record
Treen, D., Savulich, G., Mezquida, G., García-Portilla, M. P., Toll, A., García-Rizo, C., García-Álvarez, L., et al. (2019). Influence of secondary sources in the Brief Negative Symptom Scale.. Schizophr Res, 204 452-454. https://doi.org/10.1016/j.schres.2018.10.004
Negative symptoms are core symptoms of schizophrenia associated with poorer clinical outcome (Strauss et al., 2010). They can be clinically subdivided into primary and secondary features, representing different phenomenology and pathophysiological mechanisms (Miller et al., 1994). Secondary negative symptoms phenotypically present as primary symptoms, but are attributed to external causes. Positive symptom severity, depression and antipsychotic side-effects are known sources of secondary negative symptoms (Carpenter et al., 1985). Discriminating whether a negative symptom is primary or secondary is clinically relevant as it might require specific, and often opposite interventions (Miller et al., 1994). Despite the development of new symptom severity rating scales, none have considered this distinction.
Humans, Cross-Sectional Studies, Schizophrenia, Psychiatric Status Rating Scales, Adult, Middle Aged, Female, Male
Some team members have received different sources of funding that have indirectly supported this work. None of the sources of funding have had any input in the analysis or the writing of this manuscript. Dr. Savulich has been funded by a grant from Eton College and the Wallitt Foundation. Dra Mezquida has been funded by the Government of Catalonia, Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement (2014SGR441), with the grants FI-DGR-2013 Contract of the Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) (2015 FI_B2 00100) and from Fundació Bosch Gimpera (FBG) within the RETOS COLABORACIÓN 2015, funded by the Spanish Ministry of Economic Affairs and Competitiveness (RTC-2015-3440-1). Dr. Bernardo has been supported by research funding from the Spanish Ministry of Health, the Spanish Ministry of Science and Education, the Spanish Ministry of Economic Affairs andCompetitiveness, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), by Secretaria d'Univesritat i Recerca del Departament d'Economia i Coneixement (2014SGR441), Foundation European Group for Research In Schizophrenia (EGRIS), and the 7th Framework Program of the European Union. Dr. Garcia-Rizo is supported by the PI14/00753 project, integrated into the State Plan of Scientific and Technical Research and Innovation 2013–2016 and co-financed by the ISCIII-General Evaluation Branch and the European Regional Development Fund (ERDF). Dr. Bobes is supported by the Spanish Ministry of Health, the Spanish Ministry of Science and Education, the Spanish Ministry of Economic Affairs and Competitiveness and CIBERSAM. Dr. Paz-Portilla has been also supported by the European Commission, ISCIII-General Evaluation Branch and CIBERSAM. Dr. Fernanez-Egea has been supported, in part, by the NIRH-Biomedical Research Center, Cambridge. Dra. Mané has been supported in part by a grant from Hospital del Mar Medical Research Institute (IMIM).
External DOI: https://doi.org/10.1016/j.schres.2018.10.004
This record's URL: https://www.repository.cam.ac.uk/handle/1810/285934